Willow Biosciences Inc.

WLLW

CA97111B4047

Pharmaceuticals

End-of-day quote Toronto S.E. Other stock markets 23:00:00 20/05/2024 BST			5-day change	1st Jan Change
0.085 ^CAD	-5.56%		-10.53%	-15.00%

05-13	Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results	MT
05-13	Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Willow Biosciences Inc. Announces Executive Changes

August 30, 2019 at 02:21 pm

Willow Biosciences Inc. announced executive changes. The Company has appointed Jillian Hagel as Vice President, Applied Science, Chris Savile as Vice President, Commercial Operations, Dr. Mathias Schuetz as Vice President and Research and Development.

Latest news about Willow Biosciences Inc.

Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results	05-13	MT
Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Willow Biosciences Narrows 2023 Loss YOY	04-01	MT
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Willow Biosciences Announces Second Strategic Investment From Kalsec	03-01	MT
Willow Biosciences Secures Strategic Investment From Kalsec to Develop Natural Food Ingredient	02-21	MT
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.	02-19	CI
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer	01-31	MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market	01-31	CI
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally	01-31	CI
Willow Biosciences Announces Collaboration With Enterin	01-16	MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients	01-16	CI
Willow Biosciences Highlights Growth Plans for 2024, Provides 2023 Highlights	01-10	MT
Willow Biosciences Brief: Says Plans For "Significant" Growth In 2024	01-10	MT
Toronto Stocks Flat; Laurentian Bank of Canada Declines on Lower 4Q Profit, Revenue	12-07	DJ
Willow Biosciences and Nasdaq-listed Biopharma Co Advancing Development Program	12-07	MT
Willow Biosciences Brief: Willow and a Nasdaq-listed biopharma company Advancing Development Program	12-07	MT
Willow Biosciences Reports Q3 Results, Provides Update	11-15	MT
North American Morning Briefing : Stocks Seen -2-	11-15	DJ
Willow Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Aurora Cannabis Announcing Settlement of Patent Litigation	24/10/23	MT
Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding	09/10/23	CI
Willow Biosciences and Suanfarma Detail Collaboration	03/10/23	MT
Willow Biosciences Inc. and Suanfarma Announce Collaboration on Development of Large Volume Anti-Infective API Through Precision Fermentation	03/10/23	CI
Willow Biosciences Announced Company Insider Led Convertible Debenture Financing	12/09/23	MT

Chart Willow Biosciences Inc.

Duration

Period

More charts

Company Profile

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
WILLOW BIOSCIENCES INC.	-15.00%	7.91M
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.49B
BIOGEN INC.	-15.85%	32.79B
UCB	+64.13%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-21.51%	14.52B
INCYTE CORPORATION	-7.98%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.82B